Ailisi Medical Completed 173 Million Dollars of Series A Financing, Focuing on Anti-Tumor

According to iyiou.com, Ailisi Medical has completed around $173 million of Series A financing. The current round of financing was led by Shiyu Capital and followed by Loyal Valley Capital, Bioventure, SDIC, DYEE Capital and few other investment institutions. CITIC Securities serves as the financial advisor for this round of financing for Ailisi Medical.     

Founded in 2004 and headquartered in Shanghai, Ailisi Medical is committed to delivering innovative, therapeutic and marketable drugs. At present, Alice Medical has laid out corresponding research and development projects in major fields of anti-hypertension, anti-diabetes and anti-tumor, and has completed more than 50 patent applications around the world.

About this round of financing, Alice Medical said it will be mainly used to promote the follow-up clinical research and development of the efluentinib mesylate (AST2818), accelerate the commercialization of the product and promote overseas cooperation. In addition, the financing will accelerate the development of other new drugs in research and development, and the introduction of new production lines.  

The emergence of efluentinib mesylate is expected to change the choice of patients for lung cancer drugs like third-generation EGFR-targeted drug Osimertinib, developed by AstraZeneca. In terms of the selling price, the price of Ochitinib in China is around $7,500 per box, which is pretty expensive for most patients. With the advantage of domestic production, efluentinib mesylate is likely to take a share with Ochitinib, and lower the overall prices of lung cancer drugs.

Shenzhen Shiyu Investment Management Co.,Ltd. is a professional equity investment and asset management institution founded in September 2014. They are mainly focusing on equity investment in the pharmaceutical and healthcare industry, asset allocation and wealth management.

Loyal Valley Capital (LVC) is a thematic, research-driven private equity firm that invests in China. It was founded back in 2015 with $1.3 Billion of capital.

Suzhou Industrial Park Bioventure Investment Management Limited (Bioventure) was established in September 2013. Bioventure is specialized in the field of life science in the early stages of venture capital investments. It manages around 79 million dollars of capital.